Iron oxide nanoparticles may damage to the neural tissue through iron accumulation, oxidative stress, and protein aggregation

BMC Neuroscience

Volumn 18, Issue 1, 2017, Pages

  Yarjanli, Zahra ^a   Ghaedi, Kamran ^a   Esmaeili, Abolghasem ^a   Rahgozar, Soheila ^a   Zarrabi, Ali ^a  

^a UNIVERSITY OF ISFAHAN   (Iran)

Author keywords

Iron; Iron accumulation; Iron oxide nanoparticles; Neurodegenerative diseases; Oxidative stress; Protein aggregation

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CYTOCHROME C; DOPAMINE; FUNCTIONAL GROUP; GLUTATHIONE; IRON; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NEUROMELANIN; REACTIVE OXYGEN METABOLITE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; CYTOTOXIN; FERRIC ION; FERRIC OXIDE; METAL NANOPARTICLE;

5' UNTRANSLATED REGION; ALZHEIMER DISEASE; APOPTOSIS; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CONCENTRATION (PARAMETERS); DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DNA DAMAGE; FENTON REACTION; HEMOSTASIS; HUMAN; IRON RESPONSIVE ELEMENT; IRON TRANSPORT; MATERIAL COATING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE CELL NECROSIS; NERVE INJURY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARTICLE SIZE; POSITIVE FEEDBACK; PROTEIN AGGREGATION; REVIEW; SUBSTANTIA NIGRA; SURFACE CHARGE; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECT; METABOLISM; PROTEINOSIS;

ANIMALS; CENTRAL NERVOUS SYSTEM; CYTOTOXINS; FERRIC COMPOUNDS; HUMANS; IRON; METAL NANOPARTICLES; OXIDATIVE STRESS; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 85021255745     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/s12868-017-0369-9     Document Type: Review

References (70)

1. Mody VV, Cox A, Shah S, Singh A, Bevins W, Parihar H. Magnetic nanoparticle drug delivery systems for targeting tumor. Appl Nanosci. 2014;4:385-92.
2. Dikpati A, Madgulkar AR, Kshirsagar SJ, Bhalekar MR, Chahal AS. Targeted drug delivery to CNS using nanoparticles. JAPS. 2012;2(1):179-91.
3. Poduslo JF, Hultman KL, Curran GL, Preboske GM, Chamberlain R. Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid beta protein antibody-coated nanoparticles. Neuropathol Exp Neurol. 2011;70:653-61.
4. Glat M, Skaat H, Menkes-Caspi N, Margel S, Stern EA. Age-dependent effects of microglial inhibition in vivo on Alzheimer's disease neuropathology using bioactive-conjugated iron oxide nanoparticles. J Nanobiotechnol. 2013;11(32):1-12.
5. Chertok B, Moffat BA, David AE, Yu F, Bergemann C, Ross BD, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29(4):487-96.
6. Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab. 2010;30:15-35.
7. Estelrich J, Escribano E, Queralt J, Busquets MA. Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery. Int J Mol Sci. 2015;16:8070-101.
8. Malvindi MA, Matteis VD, Galeone A, Brunetti V, Anyfantis GC, Athanassiou A, et al. Toxicity assessment of silica coated iron oxide nanoparticles and biocompatibility improvement by surface engineering. PLoS One. 2014;9(1):e85835.
9. Lei L, Ling-Ling J, Yun Z, Gang L. Toxicity of superparamagnetic iron oxide nanoparticles: research strategies and implications for nanomedicine. Chin Phys B. 2013;22:1-10.
10. Mounsey RB, Teismann P. Chelators in the treatment of iron accumulation in Parkinson's disease. Int J Cell Biol. 2012. doi: 10.1155/2012/983245.
11. Farshbaf MJ, Ghaedi K. Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders? Biometals. 2016. doi: 10.1007/s10534-016-9981-x.
12. Crichton RR, Dexter DT, Ward RJ. Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm. 2011;118:301-14.
13. Acosta-Cabronero J, Cardenas-Blanco A, Betts MJ, Butryn M, Valdes-Herrera JP, Galazky I, et al. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease. Brain. 2016. doi: 10.1093/brain/aww278.
14. Lee HP, Zhu X, Liu G, Chen SG, Perry G, Smith MA, et al. Divalent metal transporter, iron, and Parkinson's disease: a pathological relationship. Cell Res. 2010;20:397-9.
15. Barbusinski K. Fenton reaction-controversy concerning the chemistry. Bioorg Chem. 2009;16:347-58.
16. Núñez MT, Urrutia P, Mena N, Aguirre P, Tapia V, Salazar J. Iron toxicity in neurodegeneration. Biometals. 2012;25:761-76.
17. Naqvi S, Samim M, Abdin MAF, Maitra A, Prashant C, Dinda AK. Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomed. 2010;16(5):983-9.
18. Lunov O, Syrovets T, Röcker C, Tron K, Nienhaus GU, Rasche V, et al. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials. 2010;31(34):9015-22.
19. Sripetchwandee J, Wongjaikam S, Krintratun W, Chattipakorn N, Chattipakorn SC. A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload. Neuroscience. 2016;332:191-202.
20. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5(1):9-19.
21. Palmieri B, Sblendorio V. Oxidative stress tests: overview on reliability and use. Part I. Eur Rev Med Pharmacol Sci. 2007;11(5):309-42.
22. Mexas LM, Florang VR, Doorn JA. Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite. Neurotoxicology. 2011;32(4):471-7.
23. Heo HJ, Lee CY. Protective effects of quercetin and vitamin C against oxidative stress-induced neurodegeneration. J Agric Food Chem. 2004;52(25):7514-7.
24. Ayton S, Lei P. Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed Res Int. 2014. doi: 10.1155/2014/581256.
25. Hare DJ, Double KL. Iron and dopamine: a toxic couple. Brain. 2016;139(4):1026-35.
26. Montes S, Rivera-Mancia S, Diaz-Ruiz A, Tristan-Lopez L, Rios C. Copper and copper proteins in Parkinson's disease. Oxid Med Cell Longev. 2014. doi: 10.1007/s10534-013-9702-7.
27. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889-909.
28. 4 nanoparticles. Langmuir. 2015;31(4):1469-78.
29. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116:1744-54.
30. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002;22(16):7006-15.
31. Liu G, Men P, Perry G, Smith MA. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol. 2010;610:123-44.
32. Butterfield DA, Swomley AM, Sultana R. Amyloid b-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal. 2013;19(8):823-35.
33. Dorostkar MM, Zou C, Blazquez-Llorca L, Herms J. Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities. Acta Neuropathol. 2015;130(1):1-19.
34. Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol. 2011;94(3):296-306.
35. Salvador GA, Uranga RM, Giusto NM. Iron and mechanisms of neurotoxicity. Int J Alzheimer's Dis. 2010. doi: 10.4061/2011/720658.
36. Everett J, Céspedes E, Shelford LR, Exley C, Collingwood JF, Dobson J, et al. Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1-42). J R Soc Interface. 2014;11:1-11.
37. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-72.
38. 2-induced apoptotic signaling via sustained activation of ASK1/JNK-p38 axis. Free Radic Biol Med. 2016;97:454-65.
39. Imam SZ, Lantz-McPeak SM, Cuevas E, Rosas-Hernandez H, Liachenko S, Zhang Y, et al. Iron oxide nanoparticles induce dopaminergic damage: in vitro pathways and in vivo imaging reveals mechanism of neuronal damage. Mol Neurobiol. 2015;52:913-26.
40. Zhang Y, Wang Z, Li X, Wang L, Yin M, Wang L, et al. Dietary iron oxide nanoparticles delay aging and ameliorate neurodegeneration in drosophila. Adv Mater. 2016;28(7):1387-93.
41. Vries HE, Kuiper J, Boer AG, Van Berkel TJC, Breimer DD. The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev. 1997;49(2):143-56.
42. Cengelli F, Maysinger D, Tschudi-Monnet F, Montet X, Corot C, Petri-Fink A, et al. Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J Pharmacol Exp Ther. 2006;318:108-16.
43. Westerink RH, Ewing AG. The PC12 cell as model for neurosecretion. Acta Physiol (Oxf). 2008;192(2):273-85.
44. Pinkernelle J, Calatayud P, Goya GF, Fansa H, Gerburg Keilhoff G. Magnetic nanoparticles in primary neural cell cultures are mainly taken up by microglia. BMC Neurosci. 2012. doi: 10.1186/1471-2202-13-32.
45. Rivet CJ, Yuan Y, Borca-Tasciuc DA, Gilbert RJ. Altering iron oxide nanoparticle surface properties induce cortical neuron cytotoxicity. Chem Res Toxicol. 2012;25(1):153-61.
46. Yang WJ, Lee JH, Hong SC, Lee J, Lee J, Han DW. Difference between toxicities of iron oxide magnetic nanoparticles with various surface-functional groups against human normal fibroblasts and fibrosarcoma cells. Materials. 2013;6:4689-706.
47. Mazuel F, Espinosa A, Luciani N, Reffay M, Borgne RL, Motte L, et al. Massive intracellular biodegradation of iron oxide nanoparticles evidenced magnetically at single-endosome and tissue levels. ACS Nano. 2016;10:7627-38.
48. Volatron J, Carn F, Kolosnjaj-Tabi J, Javed Y, Vuong QL, Gossuin Y, et al. Ferritin protein regulates the degradation of iron oxide nanoparticles. Small. 2016. doi: 10.1002/smll.201602030.
49. Laskar A, Ghosh M, Khattak SI, Li W, Yuan X. Degradation of superparamagnetic iron oxide nanoparticle-induced ferritin by lysosomal cathepsins and related immune response. Nanomedicine. 2012;7(5):705-17.
50. Yu M, Huang S, Yu KJ, Clyne AM. Dextran and polymer polyethylene glycol (PEG) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2D and 3D cell culture. Int J Mol Sci. 2012;13(5):5554-70.
51. Jarockyte G, Daugelaite E, Stasys M, Statkute U, Poderys V, Tseng TC, et al. Accumulation and toxicity of superparamagnetic iron oxide nanoparticles in cells and experimental animals. Int J Mol Sci. 2016. doi: 10.3390/ijms17081193.
52. Zhang H, Li J, Hu Y, Shen M, Shi X, Zhang G. Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancer. J Ovarian Res. 2016. doi: 10.1186/s13048-016-0230-2.
53. Diana V, Bossolasco P, Moscatelli D, Silani V, Cova L. Dose dependent side effect of superparamagnetic iron oxide nanoparticle labeling on cell motility in two fetal stem cell populations. PLoS ONE. 2013;8(11):1-12.
54. Kim ST, Saha K, Kim C, Rotello VM. The role of surface functionality in determining nanoparticle cytotoxicity. Acc Chem Res. 2013;46:681-91.
55. Wu J, Ding T, Sun J. Neurotoxic potential of iron oxide nanoparticles in the rat brain striatum and hippocampus. Neurotoxicology. 2013;34:243-53.
56. 3) nanoparticles using a simple hydrothermal strategy. J Nanomater. 2016. doi: 10.1155/2016/1920475.
57. Dashtipour K, Liu M, Kani C, Dalaie P, Obenaus A, Simmons D, et al. Iron accumulation is not homogenous among patients with Parkinson's disease. Parkinsons Dis. 2015. doi: 10.1155/2015/324843.
58. Pongrac IM, Pavičić Milić, Ahmed Brkić, Babič Horák, et al. Oxidative stress response in neural stem cells exposed to different superparamagnetic iron oxide nanoparticles. Int J Nanomed. 2016;11:1701-15.
59. Cortajarena AL, Ortega D, Ocampo SM, Gonzalez-García A, Couleaud PO, Miranda R, et al. Engineering iron oxide nanoparticles for clinical settings. Nanobiomedicine. 2014;1(2):1-20.
60. Umarao P, Bose S, Bhattacharyya S, Kumar A, Jain S. Neuroprotective potential of superparamagnetic iron oxide nanoparticles along with exposure to electromagnetic field in 6-OHDA rat model of parkinson's disease. J Nanosci Nanotechnol. 2016;16(1):261-91.
61. Zhu L, Zhou Z, Mao H, Yang L. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy. Nanomedicine. 2017;12(1):73-87.
62. Skaat H, Margel S. Newly designed magnetic and non-magnetic nanoparticles for potential diagnostics and therapy of Alzheimer's disease. J Biotechnol Biomater. 2013;3(2):1-8.
63. Farshbaf MJ, Ghaedi K, Megraw TL, Curtiss J, Faradonbeh MS, Pooneh Vaziri P, et al. Does PGC1α/FNDC5/BDNF elicit the beneficial effects of exercise on neurodegenerative disorders? NeuroMol Med. 2016;18:1-15.
64. Kumari M, Rajak S, Singh SP, Kumari SI, Kumar PU, Murty US, et al. Repeated oral dose toxicity of iron oxide nanoparticles: biochemical and histopathological alterations in different tissues of rats. J Nanosci Nanotechnol. 2012;12(3):2149-59.
65. Sarkar A, Sil PC. Iron oxide nanoparticles mediated cytotoxicity via PI3 K/AKT pathway: role of quercetin. Food Chem Toxicol. 2014;71:106-15.
66. 4 nanoparticles and ultrasound waveon MCF-7 cells. J Magn Magn Mater. 2015;394:44-9.
67. Sonmez E, Aydin E, Turkez H, Özbek E, Togar B, Meral K, et al. Cytotoxicity and genotoxicity of iron oxide nanoparticles: An in vitro biosafety study. Arch Biol Sci. 2016;68(1):7-16.
68. Szalay B, Tátrai E, Nyíro G, Vezérb T, Dura G. Potential toxic effects of iron oxide nanoparticles in in vivo and in vitro experiments. J Appl Toxicol. 2011. doi: 10.1002/jat.1779.
69. Nemmar A, Beegam S, Yuvaraju P, Yasin J, Tariq S, Attoub S, et al. Ultrasmall superparamagnetic iron oxide nanoparticles acutely promote thrombosis and cardiac oxidative stress and DNA damage in mice. Part Fibre Toxicol. 2015. doi: 10.1186/s12989-016-0132-x.
70. Zhang YQ, Dringen R, Petters C, Rastedt W, Köser J, Filserd J, et al. Toxicity of dimercaptosuccinate-coated and unfunctionalized magnetic iron oxide nanoparticles towards aquatic organisms. Environ Sci Nano. 2016;3:754-67.